Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Early B-cell development and B-cell maturation are impaired in patients with active hemophagocytic lymphohistiocytosis

Jenny Shim, Sunita Park, Suresh Venkateswaran, Deepak Kumar, Chengyu Prince, Vaunita Parihar, Larkin Maples, Edmund K. Waller, Subra Kugathasan, Michael Briones, Miyoung Lee, Curtis J. Henry, Sampath Prahalad, Shanmuganathan Chandrakasan

Blood (2023) 142 (23): 1972–1984.

https://doi.org/10.1182/blood.2023020426

Published: 2023

Includes: Supplemental data

Journal Articles

αGal9Ab Treatment As a Novel Therapy for Blood Cancer

Miyoung Lee, Curtis James Henry

Blood (2023) 142 (Supplement 1): 6056.

https://doi.org/10.1182/blood-2023-189449

Published: 2023

Journal Articles

A Novel and Potent EZH1/2 Dual Inhibitor, HM97662 Demonstrated a Wide Spectrum of Therapeutic Potential for Hematological Malignancies

Seung Hyun Jung, Jooyun Byun, Yu-Yon Kim, Seon Yeong Han, Miyoung Lee, Gunwoo Lee, Junghwa Park, Young Gil Ahn, Young Hoon Kim, Kwee Hyun Suh, Youngil Koh

Blood (2023) 142 (Supplement 1): 7134.

https://doi.org/10.1182/blood-2023-180444

Published: 2023

Journal Articles

Lyt-200, a Humanized Anti-Galectin-9 Antibody, Exhibits Preclinical Efficacy in Models of Hematological Malignancies

Curtis J Henry, Miyoung Lee, Aleksandra Filipovic

Blood (2022) 140 (Supplement 1): 8837.

https://doi.org/10.1182/blood-2022-169811

Published: 2022

Journal Articles

Combinatorial Inhibition of Galectin-9 and CHK1 Represent a Novel Treatment Strategy for T-Cell Acute Lymphoblastic Leukemia

Miyoung Lee, Aleksandra Filipovic, Curtis J Henry

Blood (2021) 138 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2021-154404

Published: 2021

Journal Articles

Interleukin-9 Promotes Chemoresistance in B-ALL Which Correlates with Decreased Bim and c-Raf Protein Expression

Jamie A.G. Hamilton, Miyoung Lee, Claire E. Pillsbury, Curtis J Henry

Blood (2021) 138 (Supplement 1): 2386.

https://doi.org/10.1182/blood-2021-153010

Published: 2021

Journal Articles

Obesity-Induced Chemoresistance in B-Cell Acute Lymphoblastic Leukemia Cells Is Mediated By Reduced Chemotherapy Uptake and Interleukin-9 Signaling

Jamie A.G. Hamilton, BS, Miyoung Lee, PhD, Ganesh R Talekar, PhD, Curtis J. Henry, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-143164

Published: 2020

Journal Articles

Obesity Attenuates T-Cell Function Which Impacts the Efficacy of T-Cell Based Immunotherapies in Acute Lymphoblastic Leukemia

Anthony Ross, MD, Miyoung Lee, PhD, Jamie Hamilton, Raira Ank, Priscilla Do, PhD, Jamie Story, Sunil S. Raikar, MD, Erik Dreaden, PhD, Christopher C. Porter, MD, Curtis J. Henry, PhD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136573

Published: 2020

Journal Articles

Elevated Levels of Interleukin-9 in Obese Microenvironments Promote Leukemia Progression and Chemoresistance in B-Cell Acute Lymphoblastic Leukemia Cells

Jamie A.G. Hamilton, BS, Miyoung Lee, PhD, Ganesh R Talekar, PhD, Curtis J. Henry, PhD

Blood (2019) 134 (Supplement_1): 1468.

https://doi.org/10.1182/blood-2019-126139

Published: 2019

Journal Articles

A Novel and Potent EZH1/2 Dual Inhibitor HM97594 for the Treatment of Hematological Malignancies

Seung Hyun Jung, PhD, DongJin Hong, MS, SeoHee Kim, MS, Jiyoung Hwang, MS, Jooyun Byun, PhD, Miyoung Lee, MS, Kyounghwa Koo, PhD, Gunwoo Lee, MS, TaeHun Song, MS, SunYoung Lim, MS, Yu-Yon Kim, PhD, Hyunjin Park, PhD, Yesol Bak, PhD, Myoungsil Ko, MS, Sunyoung Jung, MS, Yuri Han, MS, YoungGil Ahn, PhD, YoungHoon Kim, PhD, KweeHyun Suh, PhD

Blood (2019) 134 (Supplement_1): 4648.

https://doi.org/10.1182/blood-2019-122982

Published: 2019

Journal Articles

Obesity-Induced Chronic Inflammation Suppresses the Function of Non-Malignant Immune Cells While Upregulating PD-L1 on Human B-ALL Cell Lines

Miyoung Lee, PhD, Curtis J. Henry, PhD

Blood (2017) 130 (Supplement 1): 1015.

https://doi.org/10.1182/blood.V130.Suppl_1.1015.1015

Published: 2017

NARROW

Early B-cell development and B-cell maturation are impaired in patients with active hemophagocytic lymphohistiocytosis

αGal9Ab Treatment As a Novel Therapy for Blood Cancer

A Novel and Potent EZH1/2 Dual Inhibitor, HM97662 Demonstrated a Wide Spectrum of Therapeutic Potential for Hematological Malignancies

Lyt-200, a Humanized Anti-Galectin-9 Antibody, Exhibits Preclinical Efficacy in Models of Hematological Malignancies

Combinatorial Inhibition of Galectin-9 and CHK1 Represent a Novel Treatment Strategy for T-Cell Acute Lymphoblastic Leukemia

Interleukin-9 Promotes Chemoresistance in B-ALL Which Correlates with Decreased Bim and c-Raf Protein Expression

Obesity-Induced Chemoresistance in B-Cell Acute Lymphoblastic Leukemia Cells Is Mediated By Reduced Chemotherapy Uptake and Interleukin-9 Signaling

Obesity Attenuates T-Cell Function Which Impacts the Efficacy of T-Cell Based Immunotherapies in Acute Lymphoblastic Leukemia

Elevated Levels of Interleukin-9 in Obese Microenvironments Promote Leukemia Progression and Chemoresistance in B-Cell Acute Lymphoblastic Leukemia Cells

A Novel and Potent EZH1/2 Dual Inhibitor HM97594 for the Treatment of Hematological Malignancies

Obesity-Induced Chronic Inflammation Suppresses the Function of Non-Malignant Immune Cells While Upregulating PD-L1 on Human B-ALL Cell Lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only